Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. However, resistance to IM usually occurs in CML patients. The bone marrow (BM), as the predominant microenvironment of CML, secretes an abun...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaobo, Liu, Yicheng, Lu, Lu, Huang, Shaoliang, Ding, Youxiang, Zhang, Yi, Guo, Qinglong, Li, Zhiyu, Zhao, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554535/
https://www.ncbi.nlm.nih.gov/pubmed/28848440
http://dx.doi.org/10.3389/fphar.2017.00526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554535/
https://www.ncbi.nlm.nih.gov/pubmed/28848440
http://dx.doi.org/10.3389/fphar.2017.00526

Ejemplares similares